Market Overview

Erchonia Donates One Hundred and Fifty Thousand Dollars' worth of Low-Level Lasers to the New York College of Podiatric Medicine & Foot Center of New York

Share:

Pain-Free, Non-Surgical Laser Treatment Options

MELBOURNE, Fla. (PRWEB) July 25, 2018

We are pleased to announce New York College of Podiatric Medicine (NYCPM) & Foot Center of New York's (FCNY) acquisition of several Erchonia low-level lasers, including both Lunula Lasers and FX 635 Lasers. NYCPM provides unrivaled excellence in podiatric medical education and clinical experience. Their students receive comprehensive academic training and directly-supervised clinical experiences that are second to none.

The Lunula and the FX 635 low-level lasers are non-invasive, pain-free, non-thermal, non-surgical and backed by clinical trials proving their safety and effectiveness. The Lunula Laser is the 1st and only non-thermal FDA Market Cleared laser device for the temporary increase of clear nail for patients with onychomycosis, while the FX 635 is a low-level laser for the relief of chronic heel pain from plantar fasciitis. These laser technologies are breakthroughs for pain-free treatments with no known side effects or contraindications.

The donated lasers will be used by doctors and their students at the New York College of Podiatric Medicine & Foot Center of New York as solutions for conditions common in the field of podiatry, such as acute and chronic heel pain and onychomycosis (toe nail fungus).

"We at NYCPM are excited to include this technology in the care of our patients with inflammatory heel pain or onychomycosis and in the education of our students," said Michael J. Trepal, Professor of Surgery, Vice President of Academic Affairs and Academic Dean of the New York College of Podiatric Medicine.

Vice President of Erchonia Charlie Shanks said, "The Dean of New York College of Podiatric Medicine & Foot Center of New York, his staff, and students have created an environment that encourages a high standard of education. We are proud that NYCPM and FCNY have trusted us to be a part of their ongoing education and help us bring awareness of low level laser therapy (3LT®) treatment options to the podiatry field. This is a joyous occasion for the Erchonia family to be able to give back to those who have supported us and continue to help us reach our goal of being the world leaders in low level laser applications."

For more information, please visit http://www.erchonia.com.

About Erchonia
A small family company is changing the world with the most advanced non-invasive lasers on the market. Erchonia went from starting in a small garage in 1996 to selling their product in over 50 different countries around the world in 2018. Erchonia has been passionate about researching and developing low level lasers since the beginning with over (15) FDA clearances for treating chronic pain and promoting fat loss. As this family has grown so has the world of non-invasive drug-free healthcare solutions.

For the original version on PRWeb visit: https://www.prweb.com/releases/2018/07/prweb15649474.htm

View Comments and Join the Discussion!